Titre

Long-term anticoagulation treatment for acute venous thromboembolism in patients with and without cancer. The SWIss Venous ThromboEmbolism Registry (SWIVTER) II.

Type
article
Institution
UNIL/CHUV/Unisanté + institutions partenaires
Périodique
Auteur(s)
Spirk, D.
Auteure/Auteur
Ugi, J.
Auteure/Auteur
Korte, W.
Auteure/Auteur
Husmann, M.
Auteure/Auteur
Hayoz, D.
Auteure/Auteur
Baldi, T.
Auteure/Auteur
Frauchiger, B.
Auteure/Auteur
Banyai, M.
Auteure/Auteur
Aujesky, D.
Auteure/Auteur
Baumgartner, I.
Auteure/Auteur
Kucher, N.
Auteure/Auteur
Liens vers les personnes
Liens vers les unités
ISSN
0340-6245
Statut éditorial
Publié
Date de publication
2011
Volume
105
Numéro
6
Première page
962
Dernière page/numéro d’article
967
Langue
anglais
Résumé
In patients with acute cancer-associated thrombosis, current consensus guidelines recommend anticoagulation therapy for an indefinite duration or until the cancer is resolved. Among 1,247 patients with acute venous thromboembolism (VTE) enrolled in the prospective Swiss Venous Thromboembolism Registry (SWIVTER) II from 18 hospitals, 315 (25%) had cancer of whom 179 (57%) had metastatic disease, 159 (50%) ongoing or recent chemotherapy, 83 (26%) prior cancer surgery, and 63 (20%) recurrent VTE. Long-term anticoagulation treatment for >12 months was more often planned in patients with versus without cancer (47% vs. 19%; p<0.001), with recurrent cancer-associated versus first cancer-associated VTE (70% vs. 41%; p<0.001), and with metastatic versus non-metastatic cancer (59% vs. 31%; p<0.001). In patients with cancer, recurrent VTE (OR 3.46; 95%CI 1.83-6.53), metastatic disease (OR 3.04; 95%CI 1.86-4.97), and the absence of an acute infection (OR 3.55; 95%CI 1.65-7.65) were independently associated with the intention to maintain anticoagulation for >12 months. In conclusion, long-term anticoagulation treatment for more than 12 months was planned in less than half of the cancer patients with acute VTE. The low rates of long-term anticoagulation in cancer patients with a first episode of VTE and in patients with non-metastatic cancer require particular attention.
PID Serval
serval:BIB_99B5402D82A6
DOI
PMID
WOS
Permalien
Date de création
2011-09-03T18:51:16.716Z
Date de création dans IRIS
2025-05-20T22:12:19Z